BrainStorm names ex-FDA official Peter Pitts as executive chairman
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
July 28, 2026 8:00 AM EDTProfessor Jacob Frenkel Transitions to Senior Advisor
Peter J. Pitts to lead NurOwn® into Phase 3b trial; advancing under the first Special Protocol Assessment ever granted for an ALS therapeutic candidate
NEW YORK, July 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced a major... More



